Biomarin Historical Income Statement

BMRN Stock  USD 87.34  1.27  1.43%   
Historical analysis of Biomarin Pharmaceutical income statement accounts such as Interest Expense of 18 M, Selling General Administrative of 246.1 M or Total Revenue of 2.5 B can show how well Biomarin Pharmaceutical performed in making a profits. Evaluating Biomarin Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Biomarin Pharmaceutical's future profits or losses.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Biomarin Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biomarin Pharmaceutical is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.

About Biomarin Income Statement Analysis

Biomarin Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Biomarin Pharmaceutical shareholders. The income statement also shows Biomarin investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Biomarin Pharmaceutical Income Statement Chart

Biomarin Pharmaceutical Income Statement is one of the three primary financial statements used for reporting Biomarin's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Biomarin Pharmaceutical revenue and expense. Biomarin Pharmaceutical Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Biomarin Pharmaceutical's EBIT is very stable compared to the past year. As of the 29th of March 2024, Research Development is likely to grow to about 784.1 M, while Selling General Administrative is likely to drop about 246.1 M.

Total Revenue

Total revenue comprises all receipts Biomarin Pharmaceutical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Biomarin Pharmaceutical minus its cost of goods sold. It is profit before Biomarin Pharmaceutical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Biomarin Pharmaceutical. It is also known as Biomarin Pharmaceutical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most accounts from Biomarin Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Biomarin Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.At this time, Biomarin Pharmaceutical's EBIT is very stable compared to the past year. As of the 29th of March 2024, Research Development is likely to grow to about 784.1 M, while Selling General Administrative is likely to drop about 246.1 M.
 2021 2022 2023 2024 (projected)
Gross Profit1.4B1.6B1.8B1.9B
Total Revenue1.8B2.1B2.4B2.5B

Biomarin Pharmaceutical income statement Correlations

-0.220.260.80.780.750.60.640.50.810.830.710.660.380.62-0.130.550.50.55-0.160.070.80.890.430.56
-0.220.710.210.250.33-0.38-0.470.6-0.440.120.4-0.4-0.09-0.17-0.18-0.250.60.38-0.2-0.4-0.16-0.1-0.15-0.21
0.260.710.510.550.6-0.21-0.210.78-0.080.40.67-0.19-0.04-0.11-0.04-0.210.850.73-0.06-0.430.210.270.030.01
0.80.210.511.00.990.320.590.870.70.980.970.390.110.45-0.180.340.70.76-0.22-0.010.880.870.580.71
0.780.250.551.00.990.30.570.890.680.970.980.370.110.4-0.140.290.710.76-0.18-0.010.870.850.580.71
0.750.330.60.990.990.230.470.920.590.960.990.30.090.4-0.220.290.760.78-0.26-0.10.810.840.50.62
0.6-0.38-0.210.320.30.230.59-0.010.640.350.180.990.860.590.230.590.02-0.080.220.580.530.40.440.52
0.64-0.47-0.210.590.570.470.590.170.970.630.390.650.110.410.120.410.050.280.10.450.830.60.750.88
0.50.60.780.870.890.92-0.010.170.280.790.960.04-0.020.15-0.150.020.80.73-0.19-0.170.620.630.380.45
0.81-0.44-0.080.70.680.590.640.970.280.740.520.710.20.510.050.480.190.390.030.370.890.740.710.85
0.830.120.40.980.970.960.350.630.790.740.930.430.120.56-0.30.470.660.73-0.33-0.010.880.910.570.69
0.710.40.670.970.980.990.180.390.960.520.930.250.080.34-0.190.220.790.79-0.23-0.140.770.80.460.58
0.66-0.4-0.190.390.370.30.990.650.040.710.430.250.820.650.160.650.070.00.150.540.590.480.450.57
0.38-0.09-0.040.110.110.090.860.11-0.020.20.120.080.820.520.150.520.1-0.170.140.360.170.170.070.12
0.62-0.17-0.110.450.40.40.590.410.150.510.560.340.650.52-0.640.980.290.23-0.650.150.440.590.240.29
-0.13-0.18-0.04-0.18-0.14-0.220.230.12-0.150.05-0.3-0.190.160.15-0.64-0.63-0.3-0.291.00.350.02-0.280.150.19
0.55-0.25-0.210.340.290.290.590.410.020.480.470.220.650.520.98-0.630.190.16-0.630.150.380.520.190.24
0.50.60.850.70.710.760.020.050.80.190.660.790.070.10.29-0.30.190.8-0.32-0.380.410.570.120.14
0.550.380.730.760.760.78-0.080.280.730.390.730.790.0-0.170.23-0.290.160.8-0.32-0.510.510.590.270.3
-0.16-0.2-0.06-0.22-0.18-0.260.220.1-0.190.03-0.33-0.230.150.14-0.651.0-0.63-0.32-0.320.34-0.01-0.310.120.16
0.07-0.4-0.43-0.01-0.01-0.10.580.45-0.170.37-0.01-0.140.540.360.150.350.15-0.38-0.510.340.380.010.640.56
0.8-0.160.210.880.870.810.530.830.620.890.880.770.590.170.440.020.380.410.51-0.010.380.840.810.9
0.89-0.10.270.870.850.840.40.60.630.740.910.80.480.170.59-0.280.520.570.59-0.310.010.840.420.55
0.43-0.150.030.580.580.50.440.750.380.710.570.460.450.070.240.150.190.120.270.120.640.810.420.89
0.56-0.210.010.710.710.620.520.880.450.850.690.580.570.120.290.190.240.140.30.160.560.90.550.89
Click cells to compare fundamentals

Biomarin Pharmaceutical Account Relationship Matchups

Biomarin Pharmaceutical income statement Accounts

201920202021202220232024 (projected)
Depreciation And Amortization103.2M90.4M108.0M102.0M104.4M109.6M
Interest Expense23.5M29.3M15.3M16.0M17.3M18.0M
Selling General Administrative680.9M334.3M354.3M403.7M448.9M246.1M
Total Revenue1.7B1.9B1.8B2.1B2.4B2.5B
Gross Profit1.3B1.3B1.4B1.6B1.8B1.9B
Other Operating Expenses1.8B2.0B1.9B2.1B2.3B2.4B
Operating Income(125.5M)(96.3M)(60.0M)57.5M157.6M165.5M
Ebit(125.5M)(96.3M)(60.0M)57.5M157.6M165.5M
Research Development715.0M628.1M628.8M649.6M746.8M784.1M
Ebitda(22.2M)(5.9M)48.0M159.5M262.0M275.1M
Cost Of Revenue359.5M524.3M470.5M483.7M577.1M605.9M
Total Operating Expenses1.5B1.4B1.5B1.6B1.7B1.8B
Income Before Tax(94.8M)(42.3M)(75.4M)149.6M188.6M198.0M
Total Other Income Expense Net30.6M53.9M(15.3M)92.0M31.0M32.5M
Net Income(23.8M)854.0M(64.1M)141.6M167.6M176.0M
Income Tax Expense(71.0M)(901.4M)(11.3M)8.0M20.9M22.0M
Net Income Applicable To Common Shares(23.8M)859.1M(64.1M)141.6M162.8M170.9M
Net Income From Continuing Ops(23.8M)859.1M(64.1M)141.6M147.0M154.4M
Non Operating Income Net Other22.3M22.2M16.6M10.5M12.1M7.1M
Tax Provision(71.0M)(901.4M)(11.3M)8.0M4.7M4.9M
Interest Income22.7M16.6M10.5M18.0M49.0M51.5M
Net Interest Income(712K)(12.7M)(4.9M)2.1M34.1M35.8M
Reconciled Depreciation105.3M105.2M108.0M102.0M102.1M111.0M

Pair Trading with Biomarin Pharmaceutical

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Moving together with Biomarin Stock

  0.64MBRX Moleculin Biotech Financial Report 9th of May 2024 PairCorr
  0.87MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Biomarin Stock

  0.81MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.77EQ Equillium Financial Report 9th of May 2024 PairCorr
  0.76MDWD Mediwound Downward RallyPairCorr
  0.63CLVRW Clever Leaves HoldingsPairCorr
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Biomarin Stock analysis

When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Stocks Directory
Find actively traded stocks across global markets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.98
Earnings Share
0.87
Revenue Per Share
12.88
Quarterly Revenue Growth
0.202
Return On Assets
0.0163
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.